Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent

Neuroscience Letters

Volumn 350, Issue 3, 2003, Pages 187-189

  Schwarz, Anja ^a   Krätke, Oliver ^a   Burwinkel, Michael ^a   Riemer, Constanze ^a   Schultz, Julia ^a   Henklein, Peter ^b   Bamme, Theresa ^a   Baier, Michael ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Immunisation; Prion; Prophylaxis; Scrapie; Therapy

Indexed keywords

SYNTHETIC PEPTIDE; SYNTHETIC PRION PROTEIN DERIVED PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EPITOPE MAPPING; FOOD CHAIN; IMMUNIZATION; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RISK FACTOR; SCRAPIE; SCRAPIE AGENT; SURVIVAL;

EID: 0141782730     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00907-8     Document Type: Article

References (13)

1. Enari M., Flechsig E., Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl. Acad. Sci. USA. 98:2001;9295-9299.
2. Gilch S., Wopfner F., Renner-Muller I., Kremmer E., Bauer C., Wolf E., Brem G., Groschup M.H., Schatzl H.M. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J. Biol. Chem. 278:2003;18524-18531.
3. Hanan E., Goren O., Eshkenazy M., Solomon B. Immunomodulation of the human prion peptide 106-126 aggregation. Biochem. Biophys. Res. Commun. 280:2001;115-120.
4. Hanan E., Priola S.A., Solomon B. Antiaggregating antibody raised against human PrP 106-126 recognizes pathological and normal isoforms of the whole prion protein. Cell. Mol. Neurobiol. 21:2001;693-703.
5. Heppner F.L., Musahl C., Arrighi I., Klein M.A., Rulicke T., Oesch B., Zinkernagel R.M., Kalinke U., Aguzzi A. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science. 294:2001;178-182.
6. Jackson G.S., Hosszu L.L., Power A., Hill A.F., Kenney J., Saibil H., Craven C.J., Waltho J.P., Clarke A.R., Collinge J. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science. 283:1999;1935-1937.
7. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
8. Peretz D., Williamson R.A., Kaneko K., Vergara J., Leclerc E., Schmitt-Ulms G., Mehlhorn I.R., Legname G., Wormald M.R., Rudd P.M., Dwek R.A., Burton D.R., Prusiner S.B. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature. 412:2001;739-743.
9. Riemer C., Queck I., Simon D., Kurth R., Baier M. Identification of upregulated genes in scrapie-infected brain tissue. J. Virol. 74:2000;10245-10248.
10. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
11. Sigurdsson E.M., Brown D.R., Daniels M., Kascsak R.J., Kascsak R., Carp R., Meeker H.C., Frangione B., Wisniewski T. Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161:2002;13-17.
12. Sigurdsson E.M., Sy M.S., Li R., Scholtzova H., Kascsak R.J., Kascsak R., Carp R., Meeker H.C., Frangione B., Wisniewski T. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett. 336:2003;185-187.
13. White A.R., Enever P., Tayebi M., Mushens R., Linehan J., Brandner S., Anstee D., Collinge J., Hawke S. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature. 422:2003;80-83.